Myeloma kidney: Advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities

Nephrology Dialysis Transplantation

Volumn 27, Issue 10, 2012, Pages 3713-3718

  Davenport, Andrew ^a   Merlini, Giampaolo ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

bortezomib; cast nephropathy; high cut off haemodialysis; plasma exchange

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; TAMM HORSFALL GLYCOPROTEIN; THALIDOMIDE;

ACUTE KIDNEY FAILURE; AUTOLOGOUS STEM CELL TRANSPLANTATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MEGADOSE; GLOMERULONEPHRITIS; HEMODIALYSIS; HUMAN; IMMUNOGLOBULIN DEPOSITION; KIDNEY TUBULE DAMAGE; LIGHT CHAIN DEPOSITION DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN SYNTHESIS INHIBITION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SURVIVAL RATE;

ACUTE KIDNEY INJURY; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MULTIPLE MYELOMA; RENAL DIALYSIS;

EID: 84868579452     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs449     Document Type: Review

References (41)

1. Dimopoulos MA, Terpos E, Chanan-Khan A et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976-4984
2. Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 1999; 13: 79-90
3. Haynes RJ, Read S, Collins GP et al. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant 2010; 25: 419-426
4. Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992; 89: 630-639
5. Edelman GM, Cunningham BA, Gall WE et al. The covalent structure of an entire gammaG immunoglobulin molecule. Proc Natl Acad Sci USA 1969; 63: 78-85
6. Solomon A. Light chains of immunoglobulins: structural-genetic correlates. Blood 1986; 68: 603-610
7. Hutchinson AT, Jones DR, Raison RL. The ability to interact with cell membranes suggests possible biological roles for free light chain. Immunol Lett 2012; 142: 75-77
8. Hutchinson AT, Ramsland PA, Jones DR et al. Free Ig light chains interact with sphingomyelin and are found on the surface of myeloma plasma cells in an aggregated form. J Immunol 2010; 185: 4179-4188
9. Berggard I, Peterson PA. Polymeric forms of free normal kappa and lambda chains of human immunoglobulin. J Biol Chem 1969; 244: 4299-4307
10. Lavatelli F, Brambilla F, Valentini V et al. A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. Biochim Biophys Acta 2011; 1814: 409-419
11. Klassen RB, Allen PL, Batuman V et al. Light chains are a ligand for megalin. J Appl Physiol 2005; 98: 257-263
12. Kozyraki R, Fyfe J, Verroust PJ et al. Megalin-dependent cubilinmediated endocytosis is a major pathway for the apical uptake of transferrin in polarized epithelia. Proc Natl Acad Sci USA 2001; 98: 12491-12496
13. Dember LM. Light chains, casts, sheets and fibrils: monoclonal immunoglobulin diseases and immunotactoid/fibrillary glomerulopathy. Clin J Am Soc Nephrol 2006; 1: 1320-1321
14. Ronco PM, Alyanakian MA, Mougenot B et al. Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 2001; 12: 1558-1565
15. Deret S, Denoroy L, Lamarine M et al. Kappa light chain-associated Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals. Protein Eng 1999; 12: 363-369
16. Larsen CP, Bell JM, Harris AA et al. The morphologic spectrum and clinical significance of light chain proximal tubulopathy with and without crystal formation. Mod Pathol 2011; 24: 1462-1469
17. Basnayake K, Ying WZ, Wang PX et al. Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J Am Soc Nephrol 2010; 21: 1165-1173
18. Ying WZ, Wang PX, Sanders PW. Pivotal role of apoptosis signalregulating kinase 1 in monoclonal free light chain-mediated apoptosis. Am J Pathol 2012; 180: 41-47
19. Start DA, Silva FG, Davis LD et al. Myeloma cast nephropathy: immunohistochemical and lectin studies. Mod Pathol 1988; 1: 336-347
20. Ying WZ, Allen CE, Curtis LM et al. Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model. J Clin Invest 2012; 122: 1777-1785
21. Stevenson FK, Cleave AJ, Kent PW. The effect of ions on the viscometric and ultracentrifugal behaviour of Tamm-Horsfall glycoprotein. Biochim Biophys Acta 1971; 236: 59-66
22. Sanders PW. Light chain-mediated tubulopathies. Contrib Nephrol 2011; 169: 262-269
23. Ratliff TL. Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a toll-like receptor-4-dependent mechanism. J Urol 2005; 174: 1150
24. Guzman RE, Datta K, Khan NK. Obstructive protein cast nephropathy in cynomolgus monkeys treated with small organic molecules. Vet Pathol 2008; 45: 945-948
25. Hutchison CA, Batuman V, Behrens J et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 2012; 8: 43-51
26. Kyle RA, Yee GC, Somerfield MR et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007; 25: 2464-2472
27. Mhaskar R, Redzepovic J, Wheatley K et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2010: CD003188
28. Roussou M, Kastritis E, Migkou M et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomibbased regimens. Leuk Lymphoma 2008; 49: 890-895
29. Hutchison CA, Bradwell AR, Cook M et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009; 4: 745-754
30. Hutchison CA, Blade J, Cockwell P et al. Novel approaches for reducing free light chains in patients with myeloma kidney. Nat Rev Nephrol 2012; 8: 234-243
31. Cockwell P, Hutchison CA. Management options for cast nephropathy in multiple myeloma. Curr Opin Nephrol Hypertens 2010; 19: 550-555
32. Lee CK, Zangari M, Barlogie B et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823-828
33. Kastritis E, Anagnostopoulos A, Roussou M et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007; 92: 546-549
34. Jagannath S, Barlogie B, Berenson JR et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005; 103: 1195-1200
35. Ludwig H, Drach J, Graf H et al. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007; 92: 1411-1414
36. Chanan-Khan AA, Kaufman JL, Mehta J et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007; 109: 2604-2606
37. Wochner RD, Strober W, Waldmann TA. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med 1967; 126: 207-221
38. Waldmann TA, Strober W, Mogielnicki RP. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest 1972; 51: 2162-2174
39. Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 2011; 364: 2365-2366
40. Hutchison CA, Harding S, Mead G et al. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs 2008; 32: 910-917
41. Hutchison CA, Heyne N, Airia P et al. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant 2012 Epub ahead of print